About — what changed

Freshness & changelog.

Provenance you can see. Every record is dated; here is the whole library, most-recently-reviewed first, so you always know how current a ranking’s evidence is.

347 records · 0 still seed

14 Jul 2026

GapA scalable supply of insulin-producing cells
ItemAbatacept (CTLA4-Ig)
ItemAbbott Libre Duo
ItemAccu-Chek Solo micropump
TrialAdaptive platform trial: golimumab in stage 1 (presymptomatic) T1DNew
ItemAIDANET fully closed-loop algorithm
GapAlgorithms that learn you
TrialAllogeneic CD7-targeted CAR-T for T1D
ItemAndroidAPS
ItemASK (Autoimmunity Screening for Kids)
ItemAspect Biosystems bioprinted islet tissue (ex-Novo Nordisk platform)New
ItemAT278 (U500 ultra-rapid insulin aspart)
ItemAustralian T1D National Screening PilotNew
TrialAutologous CD6-CAR Tregs for stage-3 T1D
ItemAutologous polyclonal Treg therapy (T-Rex program)
ItemBaricitinib (JAK1/2 inhibitor)
ItemBeta Bionics iLet — bihormonal (insulin + dasiglucagon)
ItemBeta Bionics iLet Bionic Pancreas
ItemBeta Bionics iLet Bionic Pancreas
ItemBeta Bionics Mint (patch pump)New
ItemBeta-cell regeneration / regrowth agents
ItemBeta-O2 ßAir bioartificial pancreas (oxygen-refueled macrocapsule)
ItemBioChaperone Lispro (THDB0206)New
ItemBiolinq ShineNew
ItemCadisegliatin (oral glucokinase activator)New
TrialCadisegliatin as an adjunct for hybrid closed-loop users
TrialCadisegliatin phase 3 adjunct to insulin
ItemCamAPS FX
ItemCELZ-201 perinatal tissue-derived cell therapy
ItemCentury Therapeutics CNTY-813 (Allo-Evasion 5.0 iPSC islets)New
ItemCiPSC-derived autologous islets (RGB-5088)New
TrialCLOSE IT: open-source AID without meal announcement vs hybrid closed loopNew
TrialCNP-103: tolerogenic nanoparticles in recent-onset T1DNew
ItemCo-formulated insulin + pramlintide (single-reservoir)
TrialCommercial or open-source closed-loop impact on pregnancy
ItemConcept: closed loops that act on ketones
ItemConcept: compact dual-hormone patch with stable glucagon
TrialCOVALENT-112: icovamenib (oral menin inhibitor) in type 1 diabetesNew
ItemCRISPR Therapeutics hypoimmune islets (CTX211 → CTX213)
ItemCT-868 (acmopatide)New
ItemD1Ce Screen / Italy national screening (Law 130/2023)New
ItemDasiglucagon stable-glucagon infusion for bihormonal AID
ItemDenosumab beta-cell preservation
ItemDexcom G7
ItemDexcom G7 15-Day
ItemDexcom G8
ItemDiabeloop DBLG2
TrialDIAGNODE-3: Intralymphatic GAD-alum in HLA DR3-DQ2 recent-onset T1D
ItemDonor islet transplant (Lantidra / donislecel)
ItemE-islet 01 allogeneic human regenerative islets
TrialE-islet 01: allogeneic human regenerative islet therapy
ItemEDENT1FI (European early-detection consortium)New
ItemELSA (EarLy Surveillance for Autoimmune diabetes)
TrialENC-201-CED: Encellin encapsulated donor islets
ItemEncellin thin-film cell encapsulation (ENCRT / ENC-201)
TrialENCRT-103-hPI: Encellin's next-generation encapsulation deviceNew
ItemEOFlow EOPatch (GlucoMen Day PUMP)
TrialFABULINUS: Frexalimab CD40L blockade in recent-onset T1D
GapFinding it early enough to act
ItemFr1da (German General-Population T1D Screening)
ItemFreeStyle Libre 3 Plus
ItemFrexalimab (CD40L antagonist)
TrialFully automated insulin (Lyumjev) + pramlintide closed loop without carb countingNew
ItemFully closed-loop, insulin-only (no meal announcement)
ItemGAD-alum antigen-specific immunotherapy (Diamyd)
ItemGenprex GPX-002 (AAV Pdx1 + MafA alpha-to-beta reprogramming)
ItemGLP-1 drugs to rescue beta cells at diagnosis
ItemGlucose-responsive ("smart") insulin
ItemGlucotrack implantable CBGMNew
ItemGNTI-122 engineered Tregs (POLARIS)
ItemGolimumab (anti-TNF)
ItemiAPS
ItemIcovamenib (BMF-219) — oral menin inhibitorNew
ItemIMMUNOSTEM PD-L1 HSPC gene therapy
ItemInhaled insulin (Afrezza)
ItemInstinct sensor (made by Abbott, sold by MiniMed)New
ItemInsulin + pramlintide (amylin) closed loop
ItemInsulin aspart (NovoLog / NovoRapid)
ItemInsulin efsitora alfa (basal Fc)
GapInsulin speed: peak effect arrives ~1.5–2 hours late
TrialiPSC-derived islet cells for diabetes (Peking University First Hospital)New
ItemIslet autoantibody screening (GADA, IA-2A, ZnT8A, IAA)
TrialIslet transplantation into the anterior chamber of the eye
TrialIslet transplantation with recipient Tregs or donor bone marrow
ItemiTolerance iTOL-102 (SA-FasL microgel + islets)New
ItemKaleido patch pump
ItemKriya Therapeutics KRIYA-839 (AAV insulin + glucokinase gene therapy)
ItemLoop (iOS)
ItemLow-dose anti-thymocyte globulin (ATG)
ItemLow-dose interleukin-2 (IL-2)
GapMaking a cure last a lifetime
ItemMedtronic MiniMed 670G (first hybrid closed loop)
ItemMedtronic MiniMed 780G (SmartGuard)
ItemMiniMed Fit (patch pump)
ItemMiniMed Flex (formerly NMX8-AID)
ItemMiniMed Flex pump
ItemMiniMed Vivera (next-generation SmartGuard algorithm)New
ItemMinutia (gene-edited hypoimmune islets + graft nanosensors)New
ItemMIT oxygen-generating encapsulation device (self-oxygenating islet implant)New
ItemMixed haematopoietic chimerism (immune tolerance induction)New
ItemModular Medical Pivot patch pump
ItemNewcelX NCEL-101 / IsletRx
GapNo brakes: single-hormone loops can only stop pushing
TrialOHSU closed-loop crossover: insulin alone vs insulin plus pramlintideNew
ItemOmnipod 5 (pump)
ItemOmnipod 5 (SmartAdjust AID)
ItemOmnipod 6 (AID)
ItemOmnipod DASH (pump)
ItemOnce-weekly insulin icodec (Awiqli)
ItemOpenAPS (oref0)
TrialOPF-310 encapsulated porcine islets for unstable T1D
ItemOZTx-410 allogeneic iPSC islet cell sheet (Orizuru)New
TrialPANORAMA — bihormonal artificial pancreas after total pancreatectomyNew
ItemPLEDGE (Sanford general-population screening)
TrialPrecision ATG with or without verapamil in new-onset T1D
TrialPRISE-hATG: SAB-142 in recent-onset and established type 1 diabetesNew
GapProtecting cells without lifelong immunosuppression
ItemRepeat BCG vaccination
TrialRepeat BCG vaccination in pediatric T1D
TrialRESET T1D: rezpegaldesleukin (NKTR-358), a Treg-selective IL-2, in new-onset T1DNew
TrialRGB-5088 autologous CiPSC-derived islet injection in T1D
ItemSAB-142 (fully human anti-thymocyte globulin)New
TrialSAFEGUARD: SAB-142, a fully human anti-thymocyte globulin, in new-onset stage-3 T1DNew
ItemSana Biotechnology SC451 (hypoimmune stem-cell islets)
TrialSana SC451: hypoimmune stem-cell-derived islets without immunosuppression
ItemSenseonics Eversense 365
GapSensing: lag, accuracy, and missing analytes
ItemSequel twiist
ItemSernova Cell Pouch Bio-hybrid Organ
TrialSernova Cell Pouch: implantable islet-transplant scaffold
ItemSGLT2 / SGLT1-2 inhibitors (dapagliflozin, sotagliflozin)New
ItemSibionics GS1New
ItemSIG-002 (Lilly/Sigilon Afibromer-encapsulated islets)New
ItemSigi Patch Pump (Tandem / AMF Medical)
TrialSingle-center phase 3 islet transplantation in non-uremic T1D
TrialSotagliflozin plus volagidemab adjunct combination
ItemStem Cell Educator therapy
ItemStem-cell-derived islet clusters (Seraxis SR-02)
ItemStem-cell-derived islets (zimislecel / VX-880)
GapStopping the immune attack
TrialSTRIVE: Omnipod 5 SmartAdjust 2.0 versus Omnipod 5New
ItemT1DRA (Type 1 Diabetes Risk in Adults)New
TrialTADPOL: DFMO/polyamine pathway in recent-onset T1D
ItemTandem Control-IQ
ItemTandem Control-IQ+
ItemTandem Mobi (pump)
ItemTandem t:slim X2 (pump)
TrialTegoprubart: calcineurin-inhibitor-free islet-transplant immunosuppression
ItemTeplizumab (Tzield)
ItemTeplizumab for new-onset T1D (Tzield)
GapThe context gap: predicting blind
ItemTrio
Itemtwiist (Sequel)
ItemUltra-rapid lispro (Lyumjev)
ItemUstekinumab (IL-12/23 p40 blocker)
TrialVCTX211: CRISPR gene-edited hypoimmune stem-cell islets
ItemVerapamil (oral)
ItemVertex VX-264 (device-encapsulated stem-cell islets)
ItemViCapsys / MGH CXCL12-alginate islet encapsulation (VICAPSYN)New
TrialVX-880 / zimislecel: phase 3 in T1D with a kidney transplantNew
TrialWAVE T1D: low-dose ATG followed by adalimumab or verapamil in new-onset T1DNew
ItemZT-01 glucagon-response restorer
TrialZT-01 to prevent nocturnal hypoglycemia

14 Jun 2026

ItemAccu-Chek SmartGuideNew
TrialAdjunct therapy to reduce iatrogenic hyperinsulinemia in T1DNew
TrialAI bolus priming added to AIDANETNew
TrialAID before and during pregnancy in T1DNew
TrialAID beyond glucose metricsNew
TrialAIDANET at Home: fully closed-loop vs hybrid modesNew
TrialAIMING: AID during labor and delivery in T1DNew
TrialAllogeneic regenerative islet transplantation for brittle T1DNew
TrialAllogenic islet cell transplantation at University of ChicagoNew
TrialArgus 2.0 CGM adoption studyNew
ItemAT247 ultra-rapid insulinNew
TrialAutologous insulin-producing mesenchymal stem cells in youthNew
TrialAutologous Tregs in T1DNew
ItemAVAnT1A (early COVID-19 vaccination, GPPAD primary prevention)New
TrialCARC-101C cell therapy in autoimmune T1DNew
TrialCareSens Air 3 CGM accuracy and precisionNew
ItemCASCADE (Cascade Kids newborn screening)New
TrialCelregen CRG-002 allogeneic iPSC-derived isletsNew
ItemCelregen CRG-002 iPSC-derived isletsNew
TrialCIR-0602K insulin sensitizer for people using AIDNew
TrialCKM for safer SGLT2 inhibitor use in type 1 diabetesNew
TrialContinuous glucose-ketone monitor feasibility during pump suspensionNew
TrialContinuous ketone monitoring for safer sotagliflozin in T1D with CKDNew
TrialDapagliflozin plus pioglitazone in T1DNew
TrialDBLG1 closed-loop PROMs and glycemic controlNew
TrialDenosumab for beta-cell function in T1DNew
ItemDiabeloop DBLG1
TrialDiamyd GAD-alum in people at risk for T1DNew
ItemDimethyl fumarate for beta-cell preservationNew
TrialDimethyl fumarate for preserving beta-cell function in new-onset T1DNew
TrialEarly AID pilot in newly diagnosed T1DNew
TrialEarly AID therapy outcomes and cost-effectivenessNew
TrialEmpagliflozin added to AID systemsNew
TrialEversense Gemini flash glucose measurement studyNew
TrialEversense non-adjunctive use post-approval studyNew
TrialExtended-wear infusion set options at homeNew
TrialFCL@Home: AIDANET fully closed-loop feasibilityNew
TrialGastrin to improve islet transplantation outcomesNew
TrialGATEWAY: MiniMed Flex / NMX8-AID with Simplera SyncNew
TrialGLP-1 receptor agonist for stage-1 T1DNew
TrialGLP-1RA added around teplizumab in stage-2 T1DNew
TrialGTT@Home: home oral glucose tolerance testing for T1D screeningNew
ItemHDV-Insulin Lispro (hepatocyte-directed vesicle)New
TrialHybrid closed-loop effectiveness in adultsNew
TrialI-DIT: ixekizumab anti-IL-17 in new-onset T1DNew
TrialiLet Experience real-world safety and effectiveness studyNew
TrialIMMUNOSTEM: PD-L1 gene-modified autologous HSPCsNew
TrialINHALE-1st: Afrezza for youth with newly diagnosed T1DNew
TrialiPancreas context-aware fully closed-loop AIDNew
TrialIslet transplant with T-cell depletion and gastrinNew
TrialIslet transplantation in brittle T1DNew
TrialIslet transplantation with glucocorticoid-free immunosuppressionNew
TrialKetone monitoring to reduce DKA risk during adjunct SGLT2 inhibitionNew
TrialLabPatch glucose sensing system accuracyNew
TrialLong-term tirzepatide safety in T1D with overweight or obesityNew
TrialLow-dose glucagon before exercise while using AIDNew
TrialLuna AID system safety and effectivenessNew
TrialMATIN-2: teplizumab, intralymphatic insulin and low-dose IL-2New
TrialMedtronic implantable insulin pump system (MIIPS 2020)New
ItemMedtrum TouchCare NanoNew
TrialMiniMed 780G in T1D with gastroparesisNew
TrialMiniMed Fit Payload Wear StudyNew
TrialMTX228 adaptive phase 2 study in T1DNew
TrialNext-generation AID algorithm in adults with T1DNew
TrialOnce-weekly insulin icodec phase 3 in T1DNew
TrialOpen-source artificial pancreas use in ChinaNew
ItemOPF-310 encapsulated porcine isletsNew
ItemPIpepTolDC tolerogenic dendritic-cell vaccineNew
TrialPIpepTolDC tolerogenic dendritic-cell vaccineNew
TrialPOLARIS: GNTI-122 engineered Tregs in recent-onset T1DNew
TrialPROTECT extension: long-term teplizumab safetyNew
TrialQualitative meal-size estimation vs carb counting in AIDNew
TrialQuebec screening program for relatives of people with T1DNew
TrialReal-world insulin icodec use in type 1 diabetesNew
ItemRemygen (oral GABA) — Diamyd's beta-cell regeneration betNew
TrialRENEW: Medtrum APGO real-world AID studyNew
TrialRepeat BCG vaccination in established T1DNew
TrialROME GS continuous glucose monitoring system studyNew
TrialSafe ketone thresholds for dapagliflozin in T1DNew
TrialSanofi registry for stage 2 T1D and Tzield treatmentNew
TrialSemaglutide phase 3 in T1D with obesityNew
TrialSemaglutide to reduce carb-counting burden on closed loopNew
TrialSEMPA: semaglutide plus empagliflozin added to AIDNew
TrialSequential cord-blood stem cells and islets in monogenic immunodeficiency T1DNew
TrialSeraxis SR-02 pancreatic endocrine cells in adult T1DNew
TrialSHIELD-T1D: Shingrix and semaglutide for beta-cell preservationNew
TrialSimplified meal boluses vs carb counting in adolescents using HCLNew
TrialSorafenib in new-onset T1DNew
TrialSTRIVE 2: Omnipod 6 compared with Omnipod 5New
ItemTandem Mobi (Control-IQ+)
TrialTeplizumab in Japanese stage-2 T1DNew
TrialTeplizumab in pediatric stage-2 T1DNew
TrialThree-day and seven-day infusion set trialNew
TrialTirzepatide as an adjunct to automated insulin deliveryNew
TrialTirzepatide phase 3 in T1D with overweight or obesityNew
TrialTirzepatide with Control-IQ to reduce meal announcementsNew
TrialTregs plus anti-CD20 rituximab in pediatric stage 1 T1DNew
TrialTrialNet platform: teplizumab vs low-dose ATG to delay stage-3 T1DNew
TrialTriple therapy in T1DNew
TrialType 1 diabetes screening in pediatric primary careNew
ItemType1Screen (Australia)New
TrialUltra-rapid lispro timing in MiniMed 780GNew
TrialVerapamil to preserve residual insulin secretion in childrenNew
ItemYpsomed mylife Loop (CamAPS FX on YpsoPump)

13 Jun 2026

TrialAbatacept (CTLA4-Ig) to delay type 1 diabetes in at-risk relativesNew
ItemAbbott LingoNew
TrialADAPT: MiniMed 780G advanced hybrid closed-loop vs injections + flash CGMNew
TrialAiDAPT: Automated Insulin Delivery in Pregnancy with Type 1 DiabetesNew
ItemAlefacept (CD2 memory T-cell targeting)New
TrialASK: Autoimmunity Screening for Kids (Colorado)New
TrialBANDIT: Baricitinib (JAK inhibitor) in recent-onset type 1 diabetesNew
TrialBARICADE-DELAY: Baricitinib to delay stage-3 T1DNew
TrialBARICADE-PRESERVE: Baricitinib in newly diagnosed T1DNew
TrialBETA PRESERVE: confirmatory teplizumab trial in recent-onset stage-3 T1DNew
TrialBihormonal iLet Bionic Pancreas (insulin + glucagon) feasibility studyNew
TrialCamAPS FX hybrid closed-loop in very young children (1-7y): the KidsAP02 crossover trialNew
ItemConcept: fully closed-loop extended-wear patch pumpNew
ItemConcept: sub-20-minute glucose-responsive mealtime insulinNew
TrialControl-IQ closed-loop in children 6–13 (DCLP5 pediatric pivotal)New
TrialControl-IQ pivotal trial (iDCL): t:slim X2 closed-loop vs. sensor-augmented pumpNew
TrialCREATE-1: CELZ-201 in recent-onset type 1 diabetesNew
TrialCREATE: open-source automated insulin delivery vs sensor-augmented pumpNew
ItemDexcom ONE+New
ItemDexcom SteloNew
TrialDIAGNODE-1: First intralymphatic GAD-alum dosing studyNew
TrialDIAGNODE-2: Intralymphatic GAD-alum (Diamyd) in recent-onset type 1 diabetesNew
TrialDPT-1: Diabetes Prevention Trial-Type 1 (parenteral and oral insulin)New
TrialELSA: EarLy Surveillance for Autoimmune diabetes (UK)New
ItemFaster aspart (Fiasp)New
TrialFLAIR: MiniMed 670G vs. advanced hybrid closed-loop (the future 780G algorithm) in adolescents and young adultsNew
TrialFr1da: General-population infant/child islet-autoantibody screening (Bavaria)New
ItemFreeStyle Libre 2 PlusNew
ItemFreeStyle Libre RioNew
ItemGenetic risk score (GRS) newborn screeningNew
ItemHydroxychloroquine for stage-1 T1D preventionNew
TrialiLet Bionic Pancreas (insulin-only) pivotal trialNew
ItemImatinib (tyrosine kinase inhibitor)New
TrialImatinib in recent-onset type 1 diabetesNew
ItemInreda AP (dual-hormone)New
TrialInreda AP fully closed-loop dual-hormone artificial pancreas (DARE trial)New
ItemInsulin degludec (Tresiba)New
ItemInsulin glargine U100 (Lantus + biosimilars)New
ItemInsulin glargine U300 (Toujeo)New
ItemInsulin glulisine (Apidra)New
ItemInsulin lispro (Humalog)New
TrialJAKPOT T1D: Abrocitinib and ritlecitinib in new-onset T1DNew
TrialLantidra (donislecel): purified allogeneic islet cell therapy (CIT-07)New
TrialLow-dose anti-thymocyte globulin (ATG) ± GCSF in new-onset T1D (Haller / TrialNet)New
ItemMedtronic Guardian 4New
ItemMedtronic MiniMed 780G (pump)New
ItemMedtronic Simplera (standalone)New
TrialMiniMed 670G pivotal in-home hybrid closed-loop studyNew
ItemNon-invasive glucose monitoring (Apple, Samsung, Know Labs, Afon Glucowear)New
ItemNPH insulin (isophane / Humulin N / Novolin N)New
TrialOmnipod 5 (Horizon) pivotal single-arm AID trialNew
TrialOmnipod 5 preschool cohort (ages 2-5.9)New
ItemOmnipod 6 (pump)New
ItemOmnipod GO (pump)New
ItemOral glucose tolerance test (OGTT) for T1D stagingNew
ItemOral insulin (antigen-specific immunotherapy)New
TrialPROTECT: Teplizumab in children and adolescents with recent-onset type 1 diabetesNew
TrialProtégé: Anti-CD3 (teplizumab) in recent-onset type 1 diabetesNew
ItemRituximab (anti-CD20)New
TrialRituximab-pvvr followed by abatacept in new-onset T1D (TrialNet T1D RELAY / TN25)New
ItemSelective JAK inhibitors (abrocitinib / ritlecitinib)New
ItemSOOIL Dana Diabecare RSNew
ItemSOOIL Dana-iNew
TrialT1DAL: Alefacept in new-onset type 1 diabetesNew
ItemT1Detect (Breakthrough T1D at-home autoantibody screening)New
TrialT1GER: Golimumab in youth with new-onset type 1 diabetesNew
TrialTN-07: Oral insulin for prevention in autoantibody-positive relativesNew
TrialTN-09: Abatacept (CTLA4-Ig) in recent-onset type 1 diabetesNew
TrialTN-10: Teplizumab to delay clinical type 1 diabetes in at-risk relatives (Stage 2)New
TrialTN-22: Hydroxychloroquine in stage 1 at-risk individualsNew
ItemTrialNet Pathway to PreventionNew
TrialTrialNet Pathway to PreventionNew
TrialUST1D2: Ustekinumab phase-2/3 in adults with recent-onset T1DNew
TrialUSTEKID: Ustekinumab in adolescents with recent-onset type 1 diabetesNew
TrialVC-01: ViaCyte first-gen encapsulated stem-cell isletsNew
TrialVCTX210: first CRISPR-edited, device-encapsulated stem-cell islet productNew
TrialVerapamil to preserve beta-cell function in newly diagnosed type 1 diabetes (Ver-A-T1D)New
TrialVX-264: encapsulated stem-cell islets without immunosuppressionNew
TrialVX-880 / zimislecel: stem-cell-derived islets (with immunosuppression)New
ItemYpsomed mylife YpsoPump (pump)New

This view is generated from each record’s review date. As new evidence is ingested and rankings re-scored, updated records rise to the top. How it works →